Neoantigen-specific CD4 + tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
MacLean S HallJamie K TeerXiaoqing YuHolly BranthooverSebastian A SnedalMadeline Rodriguez-ValentinLuz NagleEllen ScottBenjamin I SchachnerPatrick InnamaratoAmy M HallJamie BlauveltCarolyn J RichAllison D RichardsJake CeccarelliT J LangerSean J YoderMatthew S BeattyCheryl A CoxJane L MessinaDaniel Abate-DagaJames J MuleJohn E MullinaxAmod A SarnaikShari Pilon-ThomasPublished in: Journal for immunotherapy of cancer (2023)
TIL in future ACT protocols as a strategy to improve antitumor immunity.